[11C]-NOP46 PET/CT Scan for Chronic Pain
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial involves giving a small amount of a new drug called [11C]-NOP46 to people with long-term pain. The drug travels to the painful areas in the body, and a camera takes pictures of these areas. This could help doctors better understand and treat long-term pain.
Do I have to stop taking my current medications for the trial?
Yes, you must stop taking pain medications 48 hours before the agent administration. If you can't, you may be withdrawn or rescheduled. Other medications may also be restricted if deemed inappropriate by the investigator.
Will I have to stop taking my current medications?
Yes, you will need to stop taking pain medications for 48 hours before the study agent is given. If you take pain medication within this time, you may be withdrawn from the study or rescheduled.
What safety data exists for [11C]-NOP46 PET/CT scans for chronic pain?
The safety data for [11C]-NOP46, also known as (11)C-NOP-1A, primarily comes from studies on its use as a PET radioligand for imaging nociceptin/orphanin FQ peptide (NOP) receptors. Research has been conducted in both rhesus monkeys and humans to assess its ability to quantify NOP receptors and estimate its radiation safety profile. These studies indicate that (11)C-NOP-1A has a high affinity for NOP receptors and an appropriate safety profile for use in brain imaging. However, specific safety data for its use in chronic pain treatment is not directly addressed in the provided research.12345
Is the [11C]-NOP46 PET/CT scan safe for humans?
Is the drug [11C]-NOP46 a promising treatment for chronic pain?
Yes, the drug [11C]-NOP46 shows promise as a treatment for chronic pain. It targets a new type of opioid receptor, which is important in managing pain. The drug has been successfully used in brain imaging to study these receptors, which could help in understanding and treating pain more effectively.24678
How does the [11C]-NOP46 PET/CT Scan treatment for chronic pain differ from other treatments?
The [11C]-NOP46 PET/CT Scan is unique because it uses a PET imaging technique to visualize the nociceptin/orphanin FQ peptide (NOP) receptors in the brain, which are a new class of opioid receptors potentially involved in pain. This approach is different from traditional pain treatments as it focuses on identifying specific brain receptor activity, which could lead to more targeted and personalized pain management strategies.24678
What data supports the idea that [11C]-NOP46 PET/CT Scan for Chronic Pain is an effective treatment?
The available research does not provide any data supporting the effectiveness of [11C]-NOP46 PET/CT Scan for Chronic Pain. The studies mentioned focus on different imaging agents and conditions, such as cancer detection and personalized radiopharmaceuticals, but do not address chronic pain or the specific treatment in question.910111213
Who Is on the Research Team?
Akiva Mintz, MD, PhD
Principal Investigator
Columbia University
Are You a Good Fit for This Trial?
This trial is for adults who can consent to participate. Healthy volunteers must not have chronic pain or be pregnant, and agree to use contraception. Patients with focal pain should experience moderate to severe pain (>4 on the Visual Analogue Scale) and also agree to contraceptive measures.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Stage 1: Healthy Volunteers
Five healthy volunteers receive a microdose of [11C]-NOP46 and undergo serial whole body PET/CT scans for up to 240 minutes to evaluate biodistribution and derive dosimetry estimates.
Stage 2: Individuals with Focal Pain
Up to 30 subjects with focal pain receive a microdose of [11C]-NOP46 and undergo PET/CT scans for up to 60 minutes to determine scanning parameters.
Follow-up
Participants are monitored for physiologic effects and uptake ratio for 48 hours post-scan.
What Are the Treatments Tested in This Trial?
Interventions
- [11C]-NOP46
Find a Clinic Near You
Who Is Running the Clinical Trial?
Columbia University
Lead Sponsor
Akiva Mintz
Lead Sponsor